YOLFTbeta
Naturalendo Tech Co Ltd

Naturalendo Tech Co Ltd

168330 · KQ · Healthcare / Biotechnology

2,100.00KRW-30.00 (-1.41%)

Price History

Full chart

Market Stats

Previous Close2,130.00
Open2,130.00
Day Range2,060.00 – 2,180.00
52-Week Range1,668.00 – 4,100.00
Volume16.66K
Market Cap75.62B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.45
50-Day Avg2,113.04
200-Day Avg2,416.58

About

Naturalendo Tech Co., Ltd. engages in the research, development, manufacture, and sale of natural product new drugs, cosmetics, materials, food additives, and health functional food in South Korea. The company offers EstroG-100, a functional raw material for women's menopause; HabaNova, a diet material; YGF 251, a phyto height growth booster; NET 2401, a multiway sleep-wake cycle regulator; Stauntonia hexaphylla Fruit Extract, an anti-inflammatory superfood; Q.186 complex for improving male menopause; NET 1701, a ultimate men's prostate and urinary support; and Quercus acuta Thunb. fruit extract for preventing skin aging caused by ultraviolet rays. It also provides daily toner pad, anti-trouble patch, cleansing gel, and mild enzyme cleansing powder under the NEEDLY brand; and bium and guma enzyme powder, haru diet burning, and bium diet clean under the NEEDIN brand. Naturalendo Tech Co., Ltd. was founded in 2001 and is headquartered in Seongnam-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Hee-do Kim
  • Employees83
  • HeadquartersC's Tower, Sampyeong-dong, Seongnam-si, South Korea, Korea
  • Websitehttps://www.naturalendo.co.kr

Leadership

  • Mr. Hee-do KimChief Executive Officer & Internal Director · b. 1973

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue124.07B44.51B6.56B9.24B8.93B13.95B18.79B22.26B22.23B
Growth (%)--64.13%-85.27%+40.92%-3.36%+56.25%+34.69%+18.48%-0.16%
Cost of Revenue39.65B13.99B6.12B5.95B12.09B12.46B12.89B12.74B12.63B
Gross Profit84.42B30.52B440.07M3.29B-3.16B1.49B5.90B9.52B9.60B
Gross Margin68.04%68.57%6.71%35.63%-35.37%10.68%31.43%42.78%43.18%
Operating Expense58.53B41.43B11.65B8.68B10.45B9.93B9.99B13.29B12.89B
Operating Income25.89B-10.91B-11.21B-5.39B-13.61B-8.44B-4.08B-3.77B-3.29B
Operating Margin20.86%-24.51%-170.99%-58.35%-152.45%-60.48%-21.72%-16.93%-14.82%
EBITDA------8.88B-3.93B-2.65B-2.52B
EBITDA Margin------63.65%-20.89%-11.92%-11.35%
Net Income20.76B-15.52B-13.18B-8.86B-19.50B-10.08B-4.37B-3.89B-3.22B
Net Income Margin16.73%-34.86%-200.99%-95.91%-218.40%-72.28%-23.25%-17.46%-14.49%
R&D2.02B2.30B1.43B1.61B2.39B1.98B2.20B2.35B2.25B
R&D as % of Total Revenue1.63%5.16%21.88%17.45%26.72%14.22%11.69%10.55%10.13%
Interest Expense0000078.14M139.63M187.32M272.04M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.56%0.74%0.84%1.22%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets88.72B69.43B85.88B85.68B61.17B39.81B37.20B33.34B35.83B
Total Liabilities17.07B18.97B38.58B30.96B24.68B3.23B6.26B6.47B12.58B
Total Equity71.65B50.46B47.30B47.62B33.13B35.45B31.08B27.20B23.98B
Cash15.13B6.63B16.31B6.45B7.23B1.24B631.59M223.79M296.18M
Net Debt------1.63B2.29B8.61B

Cash Flow

Currency: KRW2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-10.42B-7.35B-18.28B-7.52B-8.15B-4.54B-3.41B-2.14B-5.66B
Investing Cash Flow--35.46B2.83B-11.83B-1.47B9.48B----
Financing Cash Flow-1.21B-4.04B39.75B-675.40M-522.30M----
Capital Expenditure035.22B2.05B595.76M548.20M2.42B1.21B2.45B316.64M189.66M
Free Cash Flow-------5.75B-5.86B-2.45B-5.85B
FCF to OCF------126.60%171.66%114.82%103.35%

Earnings

Report DateMar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Feb 10, 2017May 12, 2017Aug 14, 2017Sep 30, 2017Feb 9, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Dec 31, 2018May 15, 2019Aug 14, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Aug 14, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------------------------------------------
EPS Actual257.32282.53321.76197.00246.79-848.69-98.12-104.35-35.52-220.99-91.15-335.28-137.48-178.54-84.97-55.56-122.58-24.45-116.64-691.65-107.43-90.55-181.51-275.29-16.91-30.1231.69-66.32-7.9321.10-54.01-123.78-62.93-94.17-42.34-121.11-40.24-7.70-25.49-64.92-36.71-28.75-30.75-26.87-25.62-31.18-20.48-24.773.42-9.89
Surprise--------------------------------------------------
Timing-----------After-hoursAfter-hoursPre-market-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-------------------After-hours--------

Key Statistics & Ratios

Market Cap75.62B
Enterprise Value83.09B
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.32
Price / Book3.14
Revenue (TTM)22.79B
Gross Profit (TTM)10.14B
EBITDA-931.64M
Profit Margin-7.16%
Operating Margin-3.15%
Return on Equity-8.83%
Return on Assets-3.07%
Shares Outstanding31.57M
Shares Float13.40M
Beta0.45
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Aug 1, 20149:5
  • Jan 15, 20142:1